Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy.

Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Group
Nephron Clin Pract. 2011 118 (4): c331-8

PMID: 21293156 · DOI:10.1159/000323139

Type 2 diabetic nephropathy (type 2 DN) patients traditionally develop significant proteinuria prior to the development of renal impairment. However, this clinical paradigm, based on observations prior to the widespread usage of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), has recently been questioned. 2,303 patients enrolled in the Sulodexide Overt Nephropathy Study (OVERT) were analyzed. Prior therapy with ACEi and/or ARB at the time of screening was recorded in 951 patients. 22% of patients had significant renal impairment with a PCR at screening of <500 mg/g. Therapy with ACEi and/or ARB at the time of screening was recorded in 94%, where prior medication data was available. In patients with type 2 DN and advanced renal impairment, levels of proteinuria below that which traditionally defines overt diabetic nephropathy, are found in more than one fifth of patients. We suggest that the high prevalence of ACEi and ARB usage in patients with type 2 DN may be effecting the traditional clinical paradigm of type 2 DN.

Copyright © 2011 S. Karger AG, Basel.

MeSH Terms (12)

Aged Biomarkers Diabetes Mellitus, Type 2 Diabetic Nephropathies Double-Blind Method Female Humans Kidney Diseases Male Middle Aged Prospective Studies Proteinuria

Connections (1)

This publication is referenced by other Labnodes entities: